GNLX
GNLX
NASDAQ · Biotechnology

Genelux Corp

$2.55
+0.13 (+5.37%)
As of Apr 1, 3:05 PM ET ·
Financial Highlights (FY 2026)
Revenue
13.6K
Net Income
-43,209,257
Gross Margin
Profit Margin
-373,362.5%
Rev Growth
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 58.3% 58.3% 58.3%
Operating Margin -391,575.0% -17.8% -22.4% -22.6%
Profit Margin -373,362.5% -18.2% -22.1% -17.2%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 13.6K 59.48M 62.40M 61.85M
Gross Profit 34.68M 36.39M 36.07M
Operating Income -53,446,071 -10,599,879 -14,003,493 -13,961,219
Net Income -43,209,257 -10,809,084 -13,759,336 -10,609,098
Gross Margin 58.3% 58.3% 58.3%
Operating Margin -391,575.0% -17.8% -22.4% -22.6%
Profit Margin -373,362.5% -18.2% -22.1% -17.2%
Rev Growth +6.2% +12.2% +11.1%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 34.63M 27.99M 31.26M
Total Equity 59.22M 51.92M 51.92M
D/E Ratio 0.58 0.54 0.60
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -44,979,122 -13,281,170 -15,040,886 -15,866,697
Free Cash Flow -10,468,769 -13,384,851 -9,996,517